Evaluation of SHR-1210 in Combination with Apatinib for Treating BRAF-Negative Mucosal Melanoma: Insights on Efficacy, Safety, and Precision Medicine Applications - Summary - MDSpire
Advertisement
Evaluation of SHR-1210 in Combination with Apatinib for Treating BRAF-Negative Mucosal Melanoma: Insights on Efficacy, Safety, and Precision Medicine Applications
To investigate the efficacy and safety of SHR-1210 (an anti-PD-1 antibody) in combination with Apatinib (a VEGFR-2 inhibitor) as late-line treatment in patients with advanced mucosal melanoma.
Key Findings:
Disease control rate (DCR) reached 100% (SD = 13), indicating potential for disease management.
Objective response rate (ORR) was 0%, highlighting a significant limitation.
Estimated median overall survival (OS) was 29.9 months (95% CI 15.26-44.54).
Estimated median progression-free survival (PFS) was 5.17 months (95% CI 3.27-10.27).
Most common adverse events were grade 1–2 hand and foot induration with desquamation and pain, with one case of grade 4 abnormal liver function and grade 3 hypertension.
Interpretation:
The combination therapy of SHR-1210 and Apatinib shows potential for disease control in mucosal melanoma, despite a low ORR, necessitating further research.
Limitations:
Small sample size of 13 patients limits statistical power.
Single-center study may limit generalizability and introduce bias.
Conclusion:
Further research with a larger sample size is needed to validate the findings and assess the efficacy of this treatment combination.
